DNLI
NASDAQ HealthcareDenali Therapeutics Inc. - Common Stock
Biotechnology
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
๐ Market Data
| Price | $18.30 |
|---|---|
| Volume | 1,495,543 |
| Market Cap | 2.90B |
| Beta | 1.100 |
| RSI (14-Day) | 42.4 |
| 200-Day MA | $17.44 |
| 50-Day MA | $20.21 |
| 52-Week High | $23.77 |
| 52-Week Low | $12.58 |
| Forward P/E | -7.08 |
| Price / Book | 2.82 |
๐ฏ Investment Strategy Scores
DNLI scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (75/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (19/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find DNLI in your text
Paste any article, transcript, or post โ the tool will extract DNLI and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.